Viewpoints

Portfolio Spotlight: Mammoth Biosciences


June 22, 2020 –

In 2018, Mayfield partnered with Trevor Martin, Janice Chen, Lucas Harrington and Jennifer Doudna on their mission to build a new-age CRISPR company by leading the Series A investment. Their vision was to transform human health with fast innovation to support the entire ecosystem in the “Intel Inside” business model. In the last six months, the company has demonstrated exceptional execution in the realization of that vision. Here are some of the big milestones the company has achieved in 2020:

Mammoth extended its CRISPR platform to next generation of gene editing CRISPR proteins and entered into an agreement to power Horizon Discovery’s cell and gene therapy manufacturing efforts.

Mammoth developed the industry’s first clinical CRISPR product with its COVID-19 lab test created with UCSF. The test demonstrated unprecedented sensitivity and accuracy with the results of the same published in Nature Biotechnology.

GlaxoSmithKline’s (GSK) consumer health unit has tied up with Mammoth to bring to market a clinical-grade CRISPR-enabled consumer self-test for COVID-19. This is a major milestone for CRISPR diagnostics in taking them mainstream.